Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (<i>EGFR</i>) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.